Accelerating Cancer Care: P1 Trials Secures $1.65M Seed Round to Revolutionize Phase 1 Oncology Trials

P1 Trials is excited to announce a major milestone in our journey toward transforming cancer care. We have successfully raised $1,650,000 in our latest funding round, which underscores the strong confidence that investors have in our innovative approach to oncology research. As a network of world-class, community-based oncology investigative sites, P1 Trials specializes in conducting complex Phase 1 clinical trials with an emphasis on standardizing and centralizing clinical trial operations. This approach not only maximizes efficiency and data quality but also significantly reduces study start-up timelines, ensuring that groundbreaking therapies reach patients faster. This injection of capital will be strategically allocated to expand our network of specialized oncology centers, allowing us to further enhance our capabilities in delivering cutting-edge experimental treatments within local communities. By bridging the critical gap between research and clinical care, our commitment to a patient-centric approach is more important than ever. The funds will also support the integration of new technologies aimed at improving the centralization process across our sites, ensuring reliable outcomes and facilitating advanced research collaborations with pharmaceutical, biotech, and CRO partners. With this new investment, P1 Trials is well-positioned to accelerate the discovery and development of innovative therapies that can significantly improve patient outcomes. Our mission to transform cancer care by making clinical trials more accessible and efficient continues to drive our strategic decisions and efforts. We remain steadfast in our dedication to groundbreaking medical advancements, ensuring that patients receive the latest and most promising experimental treatments close to home, ultimately paving the way for the future of oncology care.